CBS 2019
CBSMD教育中心
中 文

急性冠脉综合征

Abstract

Recommended Article

Clinical Efficacy and Safety of Alirocumab after Acute Coronary Syndrome According to Achieved Level of Low-Density Lipoprotein Cholesterol: A Propensity Score-Matched Analysis of the ODYSSEY OUTCOMES Trial Mortality in STEMI patients without standard modifiable risk factors: a sex-disaggregated analysis of SWEDEHEART registry data Outcome of Applying the ESC 0/1-hour Algorithm in Patients With Suspected Myocardial Infarction Colchicine Inhibits Neutrophil Extracellular Trap Formation in Patients With Acute Coronary Syndrome After Percutaneous Coronary Intervention Effects of clopidogrel vs. prasugrel vs. ticagrelor on endothelial function, inflammatory parameters, and platelet function in patients with acute coronary syndrome undergoing coronary artery stenting: a randomized, blinded, parallel study Long-term outcomes after myocardial infarction in middle-aged and older patients with congenital heart disease-a nationwide study Effect of a Restrictive vs Liberal Blood Transfusion Strategy on Major Cardiovascular Events Among Patients With Acute Myocardial Infarction and Anemia: The REALITY Randomized Clinical Trial Galectin-3 Levels and Outcomes After Myocardial Infarction: A Population-Based Study

Clinical Trial2017 Aug;47(1):133-142.

JOURNAL:Semin Arthritis Rheum. Article Link

Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study

Sparks JA, Barbhaiya M, Karlson EW et al. Keywords: Genetics; Methotrexate; Pharmacovigilance; Polyglutamate; Toxicity

FULL TEXT PDF